
After a year of troubled waters because of the Covid-19 pandemic, Coloplast has a feeling it's headed towards a more positive and stable time. The Danish medtech firm has positive expectations for the coming fiscal year, where it aims to have organic growth at 7-8 percent and earnings at between 31-32 percent.
The precise and positive expectations without notable fluctuation margins is actually based on disappointing results from the last fiscal year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app